Skip to main content
U.S. flag

An official website of the United States government

Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer’s disease

Bibliographic

Year of Publication:
2018
Contact PI Name:
Charles G. Glabe
Contact PI Affiliation:
Department of Molecular Biology and Biochemistry, University of California, Irvine, California, USA
Co-Authors:
Justyna Sosna, Stephan Philipp, Ricardo Albay III, Jorge Mauricio Reyes-Ruiz, David Baglietto-Vargas, Frank M. LaFerla
Primary Reference (PubMED ID):
Funding Source:
Alzheimer's Association
Cure Alzheimer’s Fund
National Institute on Aging (NIA)
Study Goal and Principal Findings:

Background: Besides the two main classical features of amyloid beta aggregation and tau-containing neurofibrillary tangle deposition, neuroinflammation plays an important yet unclear role in the pathophysiology of Alzheimer’s disease (AD). Microglia are believed to be key mediators of neuroinflammation during AD and responsible for the regulation of brain homeostasis by balancing neurotoxicity and neuroprotective events. We have previously reported evidence that neuritic plaques are derived from dead neurons that have accumulated intraneuronal amyloid and further recruit Iba1-positive cells, which play a role in either neuronal demise or neuritic plaque maturation or both.

Methods: To study the impact of microglia on neuritic plaque development, we treated two-month-old 5XFAD mice with a selective colony stimulation factor 1 receptor (CSF1R) inhibitor, PLX3397, for a period of 3 months, resulting in a significant ablation of microglia. Directly after this treatment, we analyzed the amount of intraneuronal amyloid and neuritic plaques and performed behavioral studies including Y-maze, fear conditioning and elevated plus maze.

Results: We found that early long-term PLX3397 administration results in a dramatic reduction of both intraneuronal amyloid as well as neuritic plaque deposition. PLX3397 treated young 5XFAD mice also displayed a significant decrease of soluble fibrillar amyloid oligomers in brain lysates, a depletion of soluble pre-fibrillar oligomers in plasma and an improvement in cognitive function measured by fear conditioning tests.

Conclusions: Our findings demonstrate that CSF1R signaling, either directly on neurons or mediated by microglia, is crucial for the accumulation of intraneuronal amyloid and formation of neuritic plaques, suggesting that these two events are serially linked in a causal pathway leading to neurodegeneration and neuritic plaque formation. CSF1R inhibitors represent potential preventative or therapeutic approach that target the very earliest stages of the formation of intraneuronal amyloid and neuritic plaques.

Therapeutic Agent

Therapeutic Information:
Therapy Type:
Small Molecule
Therapeutic Agent:
PLX3397
Therapeutic Target:
Colony Stimulating Factor 1 Receptor (CSF1R)
Therapeutic Notes:
Colony Stimulating Factor 1 Receptor (CSF1R) has been nominated as a potential target for AD. Nominated targets are obtained from several sources, including the National Institute on Aging's Accelerating Medicines Partnership in Alzheimer's Disease (AMP-AD) consortium. Targets have been identified using computational analyses of high-dimensional genomic, proteomic and/or metabolomic data derived from human samples. See Agora link for more information.

Animal Model

Model Information:
Species:
Mouse
Model Type:
APPxPS1
Strain/Genetic Background:
Not Reported

Experimental Design

Is the following information reported in the study?:
Power/Sample Size Calculation
Randomized into Groups
Blinded for Treatment
Blinded for Outcome Measures
Pharmacokinetic Measures
Pharmacodynamic Measures
Toxicology Measures
ADME Measures
Biomarkers
Dose
Formulation
Route of Delivery
Duration of Treatment
Frequency of Administration
Age of Animal at the Beginning of Treatment
Age of Animal at the End of Treatment
Sex as a Biological Variable
Study Balanced for Sex as a Biological Variable
Number of Premature Deaths
Number of Excluded Animals
Statistical Plan
Genetic Background
Inclusion/Exclusion Criteria Included
Conflict of Interest

Outcomes

Outcome Measured
Outcome Parameters
Behavioral
Contextual Fear Conditioning
Elevated Plus Maze
Exploratory Activity
Spontaneous Alternation
Y Maze
Histopathology
Activated Microglia
beta Amyloid Deposits
beta Amyloid Load
Neuritic Plaques
Biochemical
Brain-beta Amyloid Oligomers
Intracellular beta Amyloid Peptide
Brain-beta Amyloid Fibrils
Immunochemistry
Brain-beta Amyloid Deposits
Ionized Calcium Binding Adaptor Molecule 1 (Iba1)
Intracellular beta Amyloid Peptide
Microglia Morphology
Neuritic Dystrophy
Toxicology
General Behavior
General Health